Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer

Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

With immunotherapy, these single agents are being combined with targeted agents and with other immunotherapy agents, including durvalumab (Imfinzi), in an effort to enhance the amount of patients who benefit from immunotherapy, says Zandberg.

At the 2017 ASCO Annual Meeting, there were combinations with IDO inhibitors that showed promising results, explains Zandberg. The combination of anti